IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Core Insights - IMUNON, Inc. is hosting an R&D Day for investors on November 10, 2025, in New York City to provide updates on its Phase 3 study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer [1][2] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [5] - The company is developing non-viral DNA technology, with its lead clinical program, IMNN-001, aimed at localized treatment of advanced ovarian cancer [6] Clinical Trials and Research - IMNN-001 has completed multiple clinical trials, including a Phase 2 trial (OVATION 2) and is currently in a Phase 3 trial (OVATION 3) [6] - The upcoming investor event will feature presentations from thought leaders and principal investigators discussing new data on IMNN-001 and its potential impact on ovarian cancer treatment [2][7] Event Details - The event will include a live Q&A session and networking opportunities with speakers and IMUNON management, enhancing engagement with investors [2][4]